退行性二尖瓣反流的外科瓣膜修复:术式、患者选择与长期结局
综述指出二尖瓣修复因长期生存、免于瓣膜不良事件及保留左室功能优于置换,已成为重度退行性二尖瓣反流的首选术式;修复技术精炼使超过95%瓣膜可修复,15年免再手术率90%,并推动无症状患者早期手术及微创与经导管技术发展。
要点
- 二尖瓣修复是重度退行性二尖瓣反流的首选术式,长期生存与左室功能保留优于瓣膜置换。
- 修复技术精炼使超过95%的瓣膜可修复,15年免再手术率为90%。
- 推荐根据修复量、围术期影像与结局数据选择经验丰富的中心或术者处理复杂病例。
核心结论
- 二尖瓣修复因长期生存、免于瓣膜相关不良事件及保留左室功能优于瓣膜置换,已成为重度退行性二尖瓣反流的首选术式。
研究设计与样本
- 本文为综述,围绕退行性二尖瓣反流的外科修复术式、患者选择与长期结局进行总结。
主要发现
- 修复技术精炼使超过95%的瓣膜可修复,15年免再手术率为90%。
- 在修复率超过95%、死亡率低于1%的参考中心,近50%-60%接受二尖瓣修复的患者已采用该标准实践。
- 微创入路(部分胸骨切开或小切口开胸,视频辅助伴或不伴机器人)已在20%-30%的中心越来越多地开展,并声称结果与传统手术相当。
- 经导管技术特别是MitraClip正在发展并用于高危重度二尖瓣反流患者,但结果仍不理想。
关键数值与推荐
- 修复技术精炼使超过95%的瓣膜可修复,15年免再手术率为90%。
- 在修复率超过95%且死亡率低于1%的参考中心,近50%-60%接受二尖瓣修复的患者已采用标准实践。
- 微创入路已在20%-30%的中心越来越多地开展,并声称结果与传统手术相当。
临床怎么用
- 应将复杂病例转诊至修复量大、围术期影像完善且结局数据可查的经验丰富中心或术者。
- 基于良好结果,对无症状重度二尖瓣反流患者行手术已被广泛接受,以预防左室功能恶化/扩大及房颤和肺动脉高压等后果。
- 微创入路和经导管技术可用于减少创伤或治疗高危患者,但需权衡其仍不理想的结果。
局限性
- 本文为综述,未报告原始研究的具体样本量、置信区间或P值等统计细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mitral valve repair (MVRepair) has become the procedure of choice to correct severe degenerative mitral regurgitation (MR), due to its documented superiority to valve replacement regarding long-term survival, freedom from valve-related adverse events and preservation of left ventricular (LV) function. The refinement of MVRepair techniques has rendered almost all valves (more than 95%) amenable to repair with a 15-year freedom from reoperation of 90%. The concept of 'centres of excellence for MVRepair' has emerged, encouraging referring doctors to select the most experienced institutions or individual surgeons to deal with the most complex cases, based on repair volume, appropriate peri-procedural imaging and data regarding expected outcomes (repair, mortality and durability of repair). Based on the good results, operating on asymptomatic patients with severe MR is now widely accepted, prophylactically avoiding the dire consequences of chronic MR, such as LV function deterioration/enlargement, and development of atrial fibrillation and pulmonary hypertension. In reference centres, where the repair rate is over 95% for all types of disease with <1% mortality, it has become standard practice in nearly 50%-60% of all patients submitted to MVRepair. Finally, recent advances in the surgical treatment with the purpose of reducing invasiveness and surgical trauma, through partial sternotomy or mini-thoracotomy (video-assisted with or without robotics), are now being increasingly performed in 20%-30% of centres, claiming comparable results to conventional surgery. In addition, transcatheter technology, particularly the MitraClip, is evolving and treading its way in the treatment of high-risk patients with severe MR, but the results are still short of ideal.
引用
- Coutinho GF, Antunes MJ. Mitral valve repair for degenerative mitral valve disease: surgical approach, patient selection and long-term outcomes. Heart. 2017. PMID: 28566474. doi:10.1136/heartjnl-2016-311031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。